{"text": "biogen inc current quarter revenue growth yoy of 24 60 ranked 3632 out of 5610 companies in our database biib"}
{"text": "probably should look at biib also they are heavily invested in ions cns pipeline"}
{"text": "biib topline results from tofersen phase 3 study and its open label extension in sod1 als to be presented at the american neurological association annual meeting"}
{"text": "did biib express that belief they started a new trial with tofersen recently but its still among those with a sod1 mutation"}
{"text": "biib ions study looks at novel administration of spinraza via"}
{"text": "biogen price target cut at cantor fitzgerald due to lower expected sales of aduhelm biib"}
